The YS Biopharma Co Ltd (NASDAQ: YS) stock price surged 32.3% ahead of a presentation set to be delivered by its CEO at the Global Select Spotlight Emerging Growth Invitational Investor Conference later today.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.
The company’s CEO, Dr David Shao, will speak during the event, which many investors eagerly await, given the over 9.82 million YS shares traded during the premarket session. We can see that about 860,000 YS shares are traded on a typical day.
Top Broker Recommendation
- eToro Top stock trading platform with 0% commission – Read our Review
- Tickmill Regulated by the FCA – Read our Review
- Admirals (Admiral Markets) More than 4500 stocks & ETFs available – Read our Review
- Spreadex Spreadex has been around for a long time – Read our Review
- IG Top-tier regulation – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
YS Biopharma is set to attend the Global Select Spotlight Emerging Growth Invitational Investor Conference organised by Diamond Equity Research, an equity research and conference provider for small capitalisation companies.
The company’s presentation is scheduled for 10:20 a.m. Eastern Time and ends at 10:50 Eastern Time today, and Dr David Shao, YS Biopharma’s CEO, will be the presenter. YS Biopharma investors eagerly await the presentation, as evidenced by the millions of shares traded premarket.
The company's previous announcements show that the Philippine FDA approved its PIKA Rabies vaccine for a phase 3 clinical trial. The same vaccine also got similar approval in Pakistan, which could be an excellent market for the drug once it reaches commercialisation.
The two approvals occurred within two weeks, with the Pakistan approval occurring on May 16, 2023, and the Philippine approval on June 01, 2023. YS Biopharma also released its full-year 2023 results in April, which were much better than expected.
Hunter Diamond, CEO of Diamond Equity Research, said: “The Diamond Equity Research Global Select Emerging Growth Invitational offers a unique opportunity for investors to evaluate under the radar public companies with a global focus and ask relevant questions directly to management in a streamlined, convenient format – focusing on a select group of businesses as compared to larger ‘factory’ conferences.”
*This is not investment advice.
YS Biopharma stock price.
The YS Biopharma stock price had risen 32.26% to trade at $1.64, from Monday’s closing price of $1.24.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.